Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPOXX PK and Safety in Adults >120 kg
NCT04392739Phase 4Completed
- Sponsor
- SIGA Technologies
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tecovirimat in smallpox, sponsored by SIGA Technologies. Primary endpoints: Area Under the Curve from Time Zero to Last Quantifiable Concentration, Area Under the Curve from Time Zero to 24 Hours and 7 more. Started Jul 2019; status: completed.
02
Drugs
tecovirimat
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT04392739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392739.